UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.124522Principal InvestigatorAtreya, Chloe
PhaseI/II (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.MEK116833
TitleAn Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E Positive Colorectal Cancer
ObjectiveTo determine the safety, tolerability and range of tolerated combination doses in subjects with BRAF-V600E mutation-positive CRC in two dosing groups: • dabrafenib dosed orally in combination with panitumumab • trametinib dosed orally in combination with dabrafenib and panitumumab
Key EligibilityAge: 18+ * Confirmed diagnosis of advanced or metastatic BRAF V600E or V600K mutation positive colorectal cancer (CRC).
Applicable Disease SitesColon
Rectum
StatusOpen
Participating InstitutionsUniversity of California San Francisco : Jennifer Luan
Eligibility Document124522_CTGovEligibility_NCT01750918.doc
ContactJennifer Luan Phone:415-514-6220
Pager:
Email:jennifer.luan@ucsf.edu